Atrium Therapeutics Inc RNA

$8.26 -0.14 (-1.67%)

Valuation

Market cap
143,690,000
Revenue TTM
$18,760,000
Net income TTM
$-684,630,000
PE ratio
0.00
Forward PE
—
Profit margin
-3,649.41%
Debt to equity
0.00

Trading

Volume
155,700
Avg volume
306,930
Day's range
$8.20 – $8.65
Shares out
17,106,000
Stochastic %K
66%
Beta
—
Analysts
Strong Sell
Price target
$23.00

Price

Company profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyo...

Show more

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
619 876 0700
Website
https://atriumtherapeutics.com
Address
10578 Science Center Drive, Suite 125, San Diego, United States

Latest news

Stocktwits

BioTuesdays Oct 27, 4:58 PM
$RNA has announced that the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of PRKAG2 syndrome—a rare, life-threatening autosomal dominant progressive cardiomyopathy with no approved therapies. https://biotuesdays.com/2026/10/27/atrium-doses-first-patient-in-first-clinical-trial-for-patients-with-rare-cardiomyopathy/
0 replies
focafoca99 Oct 20, 12:45 PM
$RNA urged its board to launch a strategic review, curb cash spending and explain the recent dilutive financing.
0 replies
ajmrtxl Oct 9, 3:49 PM
$RNA 's latest data on SqueezeFinder
0 replies
OpenOutcrier Oct 8, 12:54 PM
$RNA (+1.1% pre) Atrium Therapeutics raises $50M in private placement https://ooc.bz/l/116944
0 replies
briefingcom Oct 8, 12:48 PM
$RNA: Atrium Therapeutics announces $50 million private placement expected to fund operations through 2028 and support lead candidates.
0 replies
Nutflush Oct 8, 11:40 AM
$RNA I'm in LFG
0 replies
flychicken1991 Oct 8, 10:34 AM
$RNA Atrium Therapeutics Announces $50 Million Private Placement. Impact: Mixed (88%). faces downward valuation pressure from 5,170,384 new shares and 1,134,930 immediately exercisable pre-funded warrants, offset by potential upward support from additional cash and reduced near-term financing risk. Source and what to watch next: https://nimpact.tech/newsimpact/news/b64fc8afa87f4ec0/rna-atrium-therapeutics-announces-50-million-private-placement?utm_source=stocktwits&utm_medium=story_url
0 replies
theBigDollarski Oct 7, 11:12 AM
$RNA oversold and trading at 1/2 the cash on hand
0 replies